PAVmed shares surge 20.03% intraday after Lucid Diagnostics unit raises $27M in public offering.

PAVmed surged 20.03% intraday after its subsidiary, Lucid Diagnostics, raised nearly $27 million through an underwritten public offering. This capital infusion, highlighted in the company’s earnings call, signals strong investor confidence in Lucid Diagnostics’ financial position and PAVmed’s strategic assets. While the stock’s debt-related risks and negative EBIT were previously emphasized in another report, the immediate price reaction aligns with the positive fundraising news, which was explicitly tied to a key operational unit. The intraday rally reflects market optimism about the fresh capital potentially bolstering PAVmed’s ability to advance its medical technology initiatives.